# Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)

> **NCT00538239** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 711 (actual)

## Conditions studied

- Metastatic Soft-Tissue Sarcomas
- Metastatic Bone Sarcomas

## Interventions

- **DRUG:** ridaforolimus
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00538239
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2010-10
- **Final completion:** 2012-12
- **Target enrollment:** 711 (ACTUAL)
- **Last updated:** 2015-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00538239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00538239, "Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00538239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*